+357 96 030922
info@marketpublishers.com

Global Carcinoembryonic Antigen Market Size study, by Application, Gender, End-user, and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G286C2208C5DEN.html
Date: May 2025
Pages: 285
Price: US$ 3,218.00 (Single User License)
ID: G286C2208C5DEN

Abstracts

The Global Carcinoembryonic Antigen (CEA) Market is valued at approximately USD 2.2 billion in 2023 and is poised to grow at a CAGR of 6.30% over the forecast period 2024–2032. Carcinoembryonic antigen, a tumor marker widely employed in the diagnosis and management of various carcinomas—particularly colorectal, gastric, pancreatic, breast, and lung cancers—has emerged as a clinical linchpin in modern oncology diagnostics. The growing reliance on tumor markers for early-stage detection, recurrence monitoring, and therapeutic assessment is driving the adoption of CEA testing. This surge is closely aligned with an expanding global cancer burden, a spike in health screening initiatives, and an increase in patient awareness regarding timely diagnosis and surveillance. As healthcare systems continue transitioning toward more proactive and preventive care models, the strategic integration of CEA tests within oncology protocols is gaining undeniable traction.

The market growth is further catalyzed by technological innovations in immunoassay platforms, the miniaturization of diagnostic devices, and the growing availability of multiplex biomarker panels. Increasing investment from public and private stakeholders in cancer screening programs, particularly in middle-income countries, is also reinforcing the demand for cost-effective, high-sensitivity biomarkers like carcinoembryonic antigen. However, the market faces challenges such as the limited specificity of CEA in certain non-cancerous conditions, which can complicate diagnosis and result in false positives. Furthermore, low awareness and underutilization of tumor markers in certain developing economies hinder full-scale market penetration.

The evolving ecosystem of cancer diagnostics is progressively favoring biomarker-guided decision-making, which has expanded the role of CEA beyond initial detection

+357 96 030922
info@marketpublishers.com

into treatment monitoring, response evaluation, and even prognosis assessment. Gender-specific prevalence trends and clinical research into hormone-related carcinomas have resulted in stratified analysis and usage of CEA testing by demographic variables. Meanwhile, hospitals and diagnostic laboratories dominate the end-user spectrum due to their extensive testing infrastructure and physician preference, although research institutions and cancer care centers are increasingly adopting companion diagnostics and personalized medicine approaches involving CEA.

Rapid digitization of diagnostic workflows, combined with the rise of decentralized testing, is also shifting the dynamics in favor of automated, point-of-care solutions. Artificial intelligence is being harnessed to improve assay sensitivity and reduce diagnostic errors, thereby enhancing the predictive value of carcinoembryonic antigen results. In parallel, the integration of CEA testing with next-generation sequencing and other molecular diagnostics is strengthening its utility in precision oncology. Emerging economies are also embracing CEA screening as a frontline diagnostic tool due to its affordability and reliability, marking a shift toward broader global standardization of cancer testing.

Regionally, North America dominates the CEA market, owing to its sophisticated healthcare infrastructure, higher screening rates, and substantial investment in oncology research. The U.S. accounts for the lion’s share, buoyed by favorable reimbursement policies and the presence of key diagnostic players. Europe follows, with national cancer registries and policy-driven screening campaigns in countries like Germany, France, and the UK. Meanwhile, the Asia Pacific region is projected to witness the fastest growth, driven by rising cancer prevalence, improving diagnostic access, and strong public health campaigns across China, India, and Southeast Asia. Latin America and the Middle East & Africa are also steadily gaining momentum as awareness and healthcare investment grow.

Major market player included in this report are:

Abbott Laboratories

Thermo Fisher Scientific, Inc.

Bio-Techne Corporation

F. Hoffmann-La Roche Ltd

+357 96 030922
info@marketpublishers.com

Quest Diagnostics Incorporated

Siemens Healthineers AG

Becton, Dickinson and Company

BioM?rieux SA

Danaher Corporation

Creative Diagnostics

GenWay Biotech Inc.

MyBioSource, Inc.

RayBiotech, Inc.

Abcam plc

Merck KGaA

The detailed segments and sub-segment of the market are explained below:

By Application

Colorectal Cancer

Pancreatic Cancer

Breast Cancer

Lung Cancer

Others

By Gender

+357 96 030922
info@marketpublishers.com

Male

Female

By End-user

Hospitals

Diagnostic Laboratories

Cancer Research Centers

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

+357 96 030922
info@marketpublishers.com

Asia Pacific

- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific

Latin America

- Brazil
- Mexico
- Rest of Latin America

Middle East & Africa

- Saudi Arabia
- South Africa
- Rest of Middle East & Africa

Years considered for the study are as follows:

- Historical year – 2022
- Base year – 2023

+357 96 030922
info@marketpublishers.com

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

+357 96 030922
info@marketpublishers.com

Contents

CHAPTER 1. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET EXECUTIVE SUMMARY

1.1. Global Carcinoembryonic Antigen Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
  1.3.1. By Application
  1.3.2. By Gender
  1.3.3. By End-user
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET DEFINITION AND RESEARCH ASSUMPTIONS

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
  2.3.1. Inclusion & Exclusion
  2.3.2. Limitations
  2.3.3. Supply Side Analysis
    2.3.3.1. Availability
    2.3.3.2. Infrastructure
    2.3.3.3. Regulatory Environment
    2.3.3.4. Market Competition
    2.3.3.5. Economic Viability (Consumer’s Perspective)
  2.3.4. Demand Side Analysis
    2.3.4.1. Regulatory Frameworks
    2.3.4.2. Technological Advancements
    2.3.4.3. Environmental Considerations
    2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET DYNAMICS

+357 96 030922
info@marketpublishers.com

3.1. Market Drivers
3.1.1. Rising Cancer Incidence and National Screening Programs
3.1.2. Innovation in Immunoassay and Point-of-Care Platforms
3.1.3. Shift Toward Preventive and Personalized Oncology Care
3.2. Market Challenges
3.2.1. Limited Specificity in Non-malignant Conditions
3.2.2. Underutilization in Emerging Economies Due to Awareness Gaps
3.3. Market Opportunities
3.3.1. Integration with AI-Enabled Diagnostic Workflows
3.3.2. Expansion of Multiplex Biomarker Panels
3.3.3. Growth Potential in Asia Pacific and Latin America

CHAPTER 4. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET INDUSTRY ANALYSIS

4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Five Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SIZE & FORECASTS BY APPLICATION 2022–2032

+357 96 030922
info@marketpublishers.com

5.1. Segment Dashboard
5.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Colorectal Cancer
5.2.2. Pancreatic Cancer
5.2.3. Breast Cancer
5.2.4. Lung Cancer
5.2.5. Others

CHAPTER 6. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SIZE & FORECASTS BY GENDER 2022–2032

6.1. Segment Dashboard
6.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Male
6.2.2. Female

CHAPTER 7. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SIZE & FORECASTS BY END-USER 2022–2032

7.1. Segment Dashboard
7.2. Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Hospitals
7.2.2. Diagnostic Laboratories
7.2.3. Cancer Research Centers
7.2.4. Others

CHAPTER 8. GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET SIZE & FORECASTS BY REGION 2022–2032

8.1. North America Market
8.1.1. U.S. Market
8.1.1.1. Application breakdown, 2022–2032
8.1.1.2. End-user breakdown, 2022–2032
8.1.2. Canada Market
8.2. Europe Market
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market

+357 96 030922
info@marketpublishers.com

8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific Market
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of Asia Pacific Market
8.4. Latin America Market
8.4.1. Brazil Market
8.4.2. Mexico Market
8.4.3. Rest of Latin America Market
8.5. Middle East & Africa Market
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of Middle East & Africa Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

9.1. Key Company SWOT Analysis
9.1.1. Abbott Laboratories
9.1.2. Thermo Fisher Scientific, Inc.
9.1.3. Bio-Techne Corporation
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Abbott Laboratories
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Thermo Fisher Scientific, Inc.
9.3.3. Bio-Techne Corporation
9.3.4. F. Hoffmann-La Roche Ltd
9.3.5. Quest Diagnostics Incorporated
9.3.6. Siemens Healthineers AG
9.3.7. Becton, Dickinson and Company

+357 96 030922
info@marketpublishers.com

9.3.8. BioM?rieux SA
9.3.9. Danaher Corporation
9.3.10. Creative Diagnostics
9.3.11. GenWay Biotech Inc.
9.3.12. MyBioSource, Inc.
9.3.13. RayBiotech, Inc.
9.3.14. Abcam plc
9.3.15. Merck KGaA

CHAPTER 10. RESEARCH PROCESS

10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Carcinoembryonic Antigen Market Size study, by Application, Gender, End-user, and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G286C2208C5DEN.html

Price: US$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G286C2208C5DEN.html